-

04:21:07 AM

Latest SCYX Stock Market News

SCYX - Scynexis Inc

06/11/21 8:30 AM

Nasdaq : SCYX

SCYNEXIS to Present at the BIO Digital International Convention 2021

SCYNEXIS, Inc. (NASDAQ: SCYX), a

RHEA-AI

neutral

06/09/21 8:30 AM

Nasdaq : SCYX

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

BREXAFEMME to receive 5-year exclusivity extension under the GAIN Act for a total of 10 years of regulatory exclusivity BREXAFEMME also protected by composition-of-matter patent until 2035 Commercial launch update call is scheduled for Tuesday, June 29 th @ 12pm ET JERSEY CITY, N.J., June 09, 2021

RHEA-AI

very positive

06/02/21 7:30 AM

Nasdaq : SCYX

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

Approval of BREXAFEMME (ibrexafungerp) represents the first approved drug in a novel antifungal class in more than 20 years BREXAFEMME, a one-day oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp development pipeline U.S. commercial launch

RHEA-AI

very positive

05/17/21 8:30 AM

Nasdaq : SCYX

SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLs Appointed Christine Coyne as Chief

RHEA-AI

positive

05/14/21 8:30 AM

Nasdaq : SCYX

SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank

Together with SCYNEXIS’ $93M cash balance at 12/31/20, the non-dilutive capital injections from this term loan, the recent licensing payments from Hansoh Pharma, and the monetization of 2020 New Jersey NOLs further strengthen SCYNEXIS’ balance sheet and projected cash runway into 2023 On track for

RHEA-AI

very positive

05/11/21 8:30 AM

Nasdaq : SCYX

SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

SCYNEXIS, Inc. (NASDAQ: SCYX), a

RHEA-AI

very positive

04/30/21 8:00 AM

Nasdaq : SCYX

SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections

A single-day dose of oral ibrexafungerp demonstrates positive clinical outcomes in difficult-to-treat vulvovaginal candidiasis (VVC) patient populations: those with non- albicans Candida VVC and/or severe VVC Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal product

RHEA-AI

neutral

04/20/21 8:00 AM

Nasdaq : SCYX

SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that two data sets from the Company’s Phase 3 VANISH Program

RHEA-AI

neutral

03/29/21 8:20 AM

Nasdaq : SCYX

SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name Brexafemme TM , and granted priority review with a PDUFA target action date of June 1, 2021 SCYNEXIS partnered with Amplity Health, a leading

RHEA-AI

neutral

03/02/21 7:30 AM

Nasdaq : SCYX

SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal infections, including those caused by resistant strains 1 st Interim analysis of CARES study shows strong

RHEA-AI

neutral

SCYX Data

industryPharmaceutical Preparation Manufacturing
websitewww.scynexis.com
ceo
security nameScynexis Inc
issue typecs
sectorManufacturing
sic code2834
employees
tagsHealth Technology,Pharmaceuticals: Other,Manufacturing,Pharmaceutical Preparation Manufacturing
address1 Evertrust Plz Fl 13
address2
stateNew Jersey
cityJersey City
zip07302-3051
countryUS
phone12018845485

SCYX Description:

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients.